HOME >> BIOLOGY >> NEWS
Chinese Condiment Cuts Blood Cholesterol

ORLANDO, Fla, March 25 -- The spice that gives Peking duck its distinctive red color seems to lower blood cholesterol, two research teams reported today at the American Heart Association's epidemiology and prevention meeting.

In a study conducted in China, an extract of the red yeast fermented on rice, which is sold under the name of Cholestin, reduced total blood cholesterol by nearly 26 percent in elderly patients after eight weeks of treatment, says the study's lead author, Joseph Chang, Ph.D., vice president of clinical affairs at Pharmanex, Inc. The Simi Valley, Calif., company imports the dietary supplement to the United States.

"Cholestin also reduced 'bad' cholesterol or low-density lipoprotein cholesterol (LDL) by 32.8 percent and decreased by 19.9 percent triglycerides, a type of blood fat associated with increased risk for heart disease," says Chang.

The average total cholesterol level of study participants was 225 milligrams/deciliter (mg/dL); average LDL was 160 mg/dL and average triglyerides were 250 mg/dL. LDL is called the "bad" cholesterol because it collects in the blood vessels to form plaque that can block blood flow, triggering a heart attack or stroke. Individuals who did not receive the supplement had reductions of total blood cholesterol and LDL of about 7 percent, says Chang.

James Rippe, M.D., associate professor of medicine at Tufts University School of Medicine in Boston, reports similar results in a second study that was conducted in 12 medical centers and funded by Pharmanex. He reports that after eight weeks on Cholestin, individuals had a 16.4 percent drop in total blood cholesterol. Their LDL decreased by 21 percent, and HDL-cholesterol, the "good" cholesterol, increased by 14.6 percent. HDL cholesterol is called the "good" cholesterol because it helps remove the "bad" cholesterol from the blood. The average cholesterol levels for this group were 242 mg/dL; average LDL was 158 mg/dL and the average HDL was
'"/>

Contact: Carole Bullock
caroleb@heart.org
214-706-1279
American Heart Association
25-Mar-1999


Page: 1 2 3

Related biology news :

1. Illustrated guidebook published for Chinese biomedical scientists and students
2. Skin condition linked to genetics in Caucasian and Chinese populations
3. Field Museum gives Parker/Gentry Award to Chinese conservationist
4. Ten Chinese reporters receive AAAS Fellowships
5. Studies probe rapid evolution of Chinese tallow trees
6. EMBO and Chinese Academy of Sciences join efforts in the area of the life sciences
7. Oncologists evaluate Chinese herbal medicine
8. Chinese tallow tree invades Texas prairies
9. Ancient Chinese folk remedy may hold key to non-toxic cancer treatment
10. Sea Grant study finds Chinese mitten crabs appear free of human parasite lung flukes
11. Nutrient in cruciferous vegetables protects against lung cancer in study of 18,244 Chinese; benefit depends on genetic factor

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Chinese Condiment Cuts Blood Cholesterol

(Date:12/10/2014)... 08, 2014 Research and Markets ... the "Biometrics Market in Japan 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 The integration of ... rural banking and upgradation of the driver,s license ... the market. Besides the aforementioned projects, biometrics is ...
(Date:12/5/2014)... 2014 Increased emphasis on product quality, ... testing and inspection technologies. The convergence of industries ... range of innovative test solutions. This trend is ... which is generally more inclined towards communication, media ... strategies of test equipment vendors will cater to ...
(Date:12/4/2014)... 3, 2014  Crossmatch™, a leading provider of ... DigitalPersona ® Pro Enterprise software and U.are.U ... throughout First Bank branch locations in ... and Virginia. First Bank, a progressive community ... North Carolina , selected the Crossmatch biometrics-based ...
Breaking Biology News(10 mins):Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3
(Date:12/19/2014)... YORK , Dec. 18, 2014 Relmada ... therapies for the treatment of chronic pain, announced the ... today. "This was a transformational year in ... promising future for our company," said Sergio Traversa ... year, we have executed on key financial, human resource ...
(Date:12/17/2014)... N.J. (PRWEB) December 17, 2014 ... (Euronext: IPN; ADR: IPSEY), today announced ... (referred to as Somatuline®) was approved by the ... treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adult ... advanced or metastatic disease to improve progression-free survival ...
(Date:12/17/2014)... 17, 2014 Audacity, a leading California-based ... member of the Huntsworth Health Group, is proud to ... team. In her role, Gonzales will serve as Senior ... incredibly honored to welcome a talent of Jamie’s caliber ... Gaëtan Fraikin. “She is a proven healthcare innovation leader ...
(Date:12/17/2014)... Mass. , Dec. 17, 2014   Synageva ... biopharmaceutical company developing therapeutic products for rare disorders, announced ... Conference being held in San Francisco, CA. ... President and Chief Executive Officer, will present on Monday, ... EST).  The presentation will be webcast live and may ...
Breaking Biology Technology:Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8Audacity Welcomes Healthcare Communications Expert Jamie Gonzales as Senior Vice President of Client Services 2
Cached News: